Structure Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)



· · THREE MONTHS ENDED · · NINE MONTHS ENDED ·
· · SEPTEMBER 30, · · SEPTEMBER 30, ·
· · 2024 · 2023 · · 2024 · 2023
Operating expenses: · · · · · · · · ·
Research and development	$32,598	$17,515	$75,327	$50,061
General and administrative	13,238	8,630	35,840	21,720
Total operating expenses	45,836	26,145	111,167	71,781
Loss from operations	(45,836)	(26,145)	(111,167)	(71,781)
Interest and other income, net	11,951	2,688	25,294	7,212
Loss before provision for income taxes	(33,885)	(23,457)	(85,873)	(64,569)
Provision for income taxes	92	405	174	548
Net loss attributable to ordinary shareholders	$(33,977)	$(23,862)	$(86,047)	$(65,117)
Net loss per share attributable to ordinary shareholders, basic and diluted	$(0.20)	$(0.21)	$(0.56)	$(0.65)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted	171,630	114,948	153,260	100,613
Other comprehensive gain (loss):
Unrealized gain (loss) on investments, net	3,326	80	2,318	(200)
Total other comprehensive gain (loss)	3,326	80	2,318	(200)
Comprehensive loss	$(30,651)	$(23,782)	$(83,729)	$(65,317)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.